316 related articles for article (PubMed ID: 28655091)
1. [Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma].
Deng SH; Xu Y; Sui WW; An G; Mao XH; Li ZJ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):487-493. PubMed ID: 28655091
[No Abstract] [Full Text] [Related]
2. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
[No Abstract] [Full Text] [Related]
3. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.
Beksac M; Seval GC; Koyun D; Topcuoglu P; Yuksel MK; Gurman G; Ilhan O
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e164-e170. PubMed ID: 36610852
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
8. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
[TBL] [Abstract][Full Text] [Related]
10. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
11. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
12. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Furlan A; Cea M; Pavan L; Galli M; Clissa C; Mangiacavalli S; Cafro AM; Girlanda S; Patriarca F; Minotto C; Bertoldero G; Barilà G; Pascarella A; Lico A; Paolini R; Rabassi N; Pescosta N; Porrazzo M; De Sabbata G; Pompa A; Bega G; Cavallin S; Guidotti F; Marcatti M; Rupolo M; Belotti A; Gherlinzoni F; Zambello R
Cancer Med; 2024 Apr; 13(7):e7071. PubMed ID: 38558233
[TBL] [Abstract][Full Text] [Related]
13. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J
BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
[TBL] [Abstract][Full Text] [Related]
18. [A retrospective study of the BiRd regimen in the treatment of relapsed/ refractory multiple myeloma].
Liu XL; Li L; Shi QL; Chen LJ; Cao XX; Li J; Liao AJ; Zou DH; Sun JN; Gao SJ; Li W; Hou J; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):837-841. PubMed ID: 29166734
[No Abstract] [Full Text] [Related]
19. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
[TBL] [Abstract][Full Text] [Related]
20. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]